Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia.
Laura W DillonGege GuiNiveditha RavindraGeorgia AndrewDevdeep MukherjeeZoë C WongYing HuangJason GerholdMatt HolmanJulian D'AngeloJeffrey MillerJake HigginsJesse J SalkJeffery J AulettaFiras El ChaerSteven M DevineAntonio Martin Jimenez-JimenezMarcos J G De LimaMark R LitzowPartow KebriaeiWael SaberStephen R SpellmanScott L ZegerKristin M PageChristopher S HouriganPublished in: JAMA oncology (2024)
This study provides generalizable and clinically applicable evidence that the detection of residual FLT3-ITD in the blood of adults in first CR from AML prior to allogeneic HCT is associated with an increased risk of relapse and death, particularly for those with a VAF of 0.01% or greater. While transplant conditioning intensification, an intervention not available to all, may help mitigate some of this risk, alternative approaches will be necessary for this high-risk population of patients who are underserved by the current standard of care.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- stem cell transplantation
- bone marrow
- end stage renal disease
- randomized controlled trial
- ejection fraction
- healthcare
- newly diagnosed
- palliative care
- hematopoietic stem cell
- quality improvement
- tyrosine kinase
- cell proliferation
- label free
- sensitive detection
- affordable care act
- breast cancer risk